Biodexa Pharmaceuticals (NASDAQ:BDRX) Cut to Sell at Wall Street Zen
by Michael Walen · The Markets DailyWall Street Zen cut shares of Biodexa Pharmaceuticals (NASDAQ:BDRX – Free Report) from a hold rating to a sell rating in a research report released on Saturday morning.
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.
View Our Latest Stock Report on Biodexa Pharmaceuticals
Biodexa Pharmaceuticals Stock Performance
BDRX stock opened at $0.81 on Friday. The business has a fifty day simple moving average of $1.53 and a 200-day simple moving average of $4.20. Biodexa Pharmaceuticals has a 52 week low of $0.77 and a 52 week high of $26.50.
Hedge Funds Weigh In On Biodexa Pharmaceuticals
An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC bought a new stake in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned 14.71% of Biodexa Pharmaceuticals as of its most recent filing with the SEC. 17.51% of the stock is currently owned by institutional investors.
Biodexa Pharmaceuticals Company Profile
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.